The biological basis and translational challenges of de novo and acquired resistance related to targets, payloads, and tumor microenvironmental constraints, as well as the implications of these mechanisms for biomarker development, sequencing rationales, and combination strategies with immune checkpoint inhibitors and...
Chen-Xu Guo, L. Ellisen· Journal of Clinical Investig...· 0 citations
This large collection of MBC cfDNA data is envisioned as an invaluable resource for the design and planning of future clinical trials, and cfDNA testing is now recommended in multiple advanced malignancies, including eligibility assessment for clinical trials.
I. Leshchiner, A. Medford, J. Cha et al.· Nature Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.